ClinicalTrials.gg
TerminatedNCT06425874Updated Nov 19, 2026

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery

An observational study in Breast Cancer, Surgery and Quality of Life, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Terminated at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

Why this study was terminated
Funding issues.
Updated Nov 19, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
321
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 59 open to participants now, 67 under way, 18 of them phase 3. Breast Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Enrollment
11th of 29
321 · median 220
Started
2024
with 13 others
Observational
29 of 101
11 open now
Registered
64th of 101
by date

Among the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 11th largest by enrollment of the 29 observational ones that give a count, is one of 14 that started in 2024, is one of 29 observational ones, and was the 64th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

59 of the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

54 more — sign in →

By country, each count listing its studies:

All 59 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 50 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

Breast-conserving surgery is the standard treatment for young breast cancer patients, while mastectomy with breast reconstruction is an alternative for those who are not eligible for Breast-conserving surgery. Several studies have compared the quality of life and patient satisfaction among individuals receiving different types of surgery (Breast-conserving surgery, mastectomy alone, or mastectomy with reconstruction). For example, Meghan R. demonstrated that patients undergoing Breast-conserving surgery experience a higher quality of life compared to those undergoing mastectomy with breast reconstruction, whereas J. Dauplat's study showed that patients who undergo mastectomy with breast reconstruction report a higher quality of life than those who undergo mastectomy alone.

However, the investigators hypothesize that the advantages of a specific type of surgery over another, such as Breast-conserving surgery versus breast reconstruction, may vary among patients with different socioeconomic factors. For instance, the benefits of breast reconstruction over Breast-conserving surgery might be more pronounced in young patients who require a more socially active lifestyle.

Additionally, the benefits of one type of surgery over another may also vary at different time points during post-operative follow-up. Furthermore, it is worth noting that most current studies have been conducted in Caucasian populations. In contrast to Caucasians, Asians typically have smaller breast volumes, potentially leading to more significant defects after Breast-conserving surgery and possibly poorer aesthetic outcomes. Therefore, a study focusing on Asian young breast cancer populations is necessary.

Read the detailed description

This study is a prospective, observational cohort study aiming to enroll 1000 young Chinese breast cancer patients and assign them to three arms: Breast-conserving surgery, mastectomy alone, and mastectomy with breast reconstruction, based on their clinical decisions and preferences. Clinicopathological features (age,Tumor, Node, Metastasis stages, pathological features, etc.), socioeconomic determinants (education level, income, insurance status, marital status, occupational status, personality, etc.), treatment information (neoadjuvant chemotherapy or not, post-operative complications), and survival (local recurrence, metastasis) will be recorded.

All patients will be followed at 6 and 12 months for the first year after diagnosis, then yearly thereafter for an additional 9 years (for a total follow-up of at least 10 years following diagnosis). During the post-operative follow-up, quality of life, psychological well-being, decision regret, surgical information, treatment costs, and surveillance-follow-up will be recorded.

The primary endpoint of this study is the quality of life, assessed using the Breast-Q and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Secondary endpoints include decisional conflict scale, decision regret scales, and the Hospital Anxiety and Depression Scale (HADS).

The primary and secondary endpoints will be compared among the three arms, and the impact of socioeconomic determinants at baseline on these endpoints will also be investigated. Additionally, the investigators aim to explore the potential of a novel subtyping method for young breast cancer patients using selected socioeconomic determinants.

03

Conditions studied

  • Breast Cancer
  • Surgery
  • Quality of Life

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Young breast cancer women.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 50 years old.
  • The surgery time and procedure have been confirmed, and the surgical and research informed consent forms have been signed.
  • Informed consent obtained from patient.
  • Unilateral Breast Cancer.
  • Good health,the patient is able to tolerate general anesthesia and surgery, with an performance status of ≤2 points.
  • No history of breast/axillary radiation therapy.
  • Willing and capable of complying with the study protocol visits, treatment plans, and other research procedures.

Exclusion criteria

Exclusion Criteria:

  • Bilateral breast cancer.
  • Inflammatory breast cancer.
  • Stage IV breast cancer.
  • Physical examination and imaging suggest tumor infiltration into the skin, pectoralis major muscle, and other adjacent tissues.
  • Patients unable to tolerate surgery due to coagulation abnormalities.
  • In patients without evidence of breast cancer in the contralateral breast, requesting contralateral prophylactic mastectomy.
  • In patients who have undergone surgical treatment for breast cancer (including mastectomy, breast-conserving surgery, and mastectomy with implant reconstruction), requesting secondary breast surgery.
  • Patients with a history or current diagnosis of other , excluding thyroid cancer.
  • The conditions considered unsuitable for inclusion by researchers.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
321 participants (actual)
Patient registry
No

Groups and cohorts

  • Breast-conserving surgery

    Procedure: Breast-conserving surgery

  • Mastectomy

    Procedure: Mastectomy

  • Mastectomy with reconstruction

    Procedure: Mastectomy with reconstruction

Interventions

  • ProcedureBreast-conserving surgery

    Breast-conserving surgery

  • ProcedureMastectomy

    Mastectomy without reconstruction

  • ProcedureMastectomy with reconstruction

    Any type of reconstruction(include implant and autologous)

06

What researchers measure

Primary outcomes

  1. Participant's breast satisfaction assessed by BREAST-Q questionnaire version 2.0

    Utilizing the BREAST-Q questionnaire, this measure assesses women's self-reported satisfaction with their breasts and associated quality of life, encompassing psychosocial, sexual, and physical well-being. Scores range from 0 (worst) to 100 (best), with higher scores indicating a more favorable outcome.Assessment is conducted preoperatively and 10 years postoperatively.

    Time frame: Pre-operation and 10 years

  2. Participant's health-related quality of life assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Assessed through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), this self-administered questionnaire consists of 30 items designed to evaluate the health-related quality of life among cancer patients. For questions 1 to 28, a 4-point scale is used, ranging from 1 ("Not at all") to 4 ("Very much"), with lower scores indicating a more positive outcome. Questions 29 and 30 employ a 7-point scale, with scores ranging from 1 ("Very poor") to 7 ("Excellent"), where higher scores signify a better outcome.Assessment is conducted 10 years postoperatively.

    Time frame: 10 years

Secondary outcomes

  1. Participant's decisional conflict assessed by Decisional Conflict Scale questionnaire

    Administered pre-operation, this tool evaluates the patient's conflict regarding the decision for surgery. Each item is rated on a Likert Scale with five responses, ranging from 0 ("Not at All") to 4 ("Extremely"), resulting in a total score ranging from 0 (Less conflicted) to 100 (Highly conflicted).Assessment is conducted preoperatively.

    Time frame: Pre-Operative

  2. Participant's decision regret assessed by Decision Regret Scale questionnaire

    Conducted during follow-up sessions, this assessment captures the patient's sentiments and remorse regarding the treatment-related decision to undergo surgery. Five items specifically inquire about feelings of regret. Scores range from 0 to 100, with a higher score indicating a greater level of decision-related regret.Assessment is conducted 10 years postoperatively.

    Time frame: 10 years

  3. Participant's anxiety and depression assessed by Hospital Anxiety and Depression Scale questionnaire

    Administered during follow-ups, this scale measures the patient's psychological change. The HADS comprises two 7-item subscales assessing depression and anxiety symptoms separately. Higher scores indicate greater levels of depression and/or anxiety.Assessment is conducted preoperatively and 10 years postoperatively.

    Time frame: Pre-operation and 10 years

Other outcomes

  1. Influence of Socioeconomic, Psychological, and Clinicopathological Factors on Outcomes

    Exploring the Influence of Socioeconomic, Psychological, and Clinicopathological Features on Primary and Secondary Outcomes.

    Time frame: Pre-operation and 10 years

07

Study locations

1 site
08

References and documents

Publications

  • Dominici L, Hu J, Zheng Y, Kim HJ, King TA, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Wong JS, Partridge AH, Rosenberg SM. Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surg. 2021 Oct 1;156(10):e213758. doi: 10.1001/jamasurg.2021.3758. Epub 2021 Oct 13. PubMed 34468718 ↗
  • Hanson SE, Lei X, Roubaud MS, DeSnyder SM, Caudle AS, Shaitelman SF, Hoffman KE, Smith GL, Jagsi R, Peterson SK, Smith BD. Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg. 2022 Jun 1;157(6):e220631. doi: 10.1001/jamasurg.2022.0631. Epub 2022 Jun 8. PubMed 35416926 ↗
  • Diao K, Lei X, He W, Jagsi R, Giordano SH, Smith GL, Caudle A, Shen Y, Peterson SK, Smith BD. Patient-reported Quality of Life After Breast-conserving Surgery With Radiotherapy Versus Mastectomy and Reconstruction. Ann Surg. 2023 Nov 1;278(5):e1096-e1102. doi: 10.1097/SLA.0000000000005920. Epub 2023 May 26. PubMed 37232937 ↗
  • Rosenberg SM, Dominici LS, Gelber S, Poorvu PD, Ruddy KJ, Wong JS, Tamimi RM, Schapira L, Come S, Peppercorn JM, Borges VF, Partridge AH. Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. JAMA Surg. 2020 Nov 1;155(11):1035-1042. doi: 10.1001/jamasurg.2020.3325. PubMed 32936216 ↗
  • Riba LA, Gruner RA, Alapati A, James TA. Association between socioeconomic factors and outcomes in breast cancer. Breast J. 2019 May;25(3):488-492. doi: 10.1111/tbj.13250. Epub 2019 Apr 15. PubMed 30983100 ↗
  • Flanagan MR, Zabor EC, Romanoff A, Fuzesi S, Stempel M, Mehrara BJ, Morrow M, Pusic AL, Gemignani ML. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. Ann Surg Oncol. 2019 Oct;26(10):3133-3140. doi: 10.1245/s10434-019-07548-9. Epub 2019 Jul 24. PubMed 31342397 ↗
  • Dauplat J, Kwiatkowski F, Rouanet P, Delay E, Clough K, Verhaeghe JL, Raoust I, Houvenaeghel G, Lemasurier P, Thivat E, Pomel C; STIC-RMI working group. Quality of life after mastectomy with or without immediate breast reconstruction. Br J Surg. 2017 Aug;104(9):1197-1206. doi: 10.1002/bjs.10537. Epub 2017 Apr 12. PubMed 28401542 ↗

Individual participant data

Plan to share: No — The study protocol and the raw and clean data for analysis will be shared among the participated researchers. Non-researchers could obtain relevant informations from the researchers upon reasonable requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Nov 2026, 32 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2035 → Nov 2026 and completion Dec 2035 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 22, 2024
StartActual
Feb 29, 2024
Primary completionActual
Nov 11, 2026was Dec 2035
CompletionActual
Nov 11, 2026was Dec 2035
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Funding issues.
changed Nov 19, 2026
Primary completion
Dec 1, 2035→Nov 11, 2026 (actual)
Nov 19, 2026
Study completion
Dec 1, 2035→Nov 11, 2026 (actual)
Nov 19, 2026
Enrollment
1000 (estimated)→321 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Terminated
    Why stopped Funding issues.
    Primary completion Dec 1, 2035→Nov 11, 2026 (now actual)
    Study completion Dec 1, 2035→Nov 11, 2026 (now actual)
    Enrollment 1000 (estimated)→321 (actual)
    + 4 other changes: verification date, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06425874
Responsible party
Chen Kai (Clinical Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
May 22, 2024
Start date
Feb 29, 2024
Primary completion
Nov 11, 2026
Completion
Nov 11, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion